"Medicare's Top Drugs for Price Negotiation Revealed"
TL;DR Summary
The Biden administration has released a list of ten drugs subject to price negotiations with Medicare, aiming to lower drug costs for older adults. The most widely used drugs on the list are Bristol-Myers Squibb's blood thinner Eliquis, Boehringer Ingelheim's diabetes medication Jardiance, and Johnson & Johnson's blood thinner Xarelto. Medicare Part D spent $16.5 billion on Eliquis, $7 billion on Jardiance, and $6 billion on Xarelto from June 2022 to May 2023. The negotiations will conclude in August 2024, with reduced prices taking effect in January 2026.
Topics:top-news#blood-thinners#diabetes-medication#drug-prices#healthcare#medicare#price-negotiations
- Here are the three most used drugs on the Medicare price negotiation list CNBC
- Eliquis and Jardiance Among First Drugs Picked for Medicare Price Negotiations The New York Times
- Cutting Health Care Costs The New York Times
- Medicare Drug Price Negotiation: First List of Medicines, Explained Bloomberg
- The slippery slope of price controls on prescription drugs The Hill
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
76%
369 → 88 words
Want the full story? Read the original article
Read on CNBC